Have a baseline BMI (prior to any weight-loss treatment) of 30 or 25 with one or more previously diagnosed conditions: Controlled Type II Diabetes, Sleep Apnea, High Cholesterol, High Triglycerides, Prediabetes, High Blood Pressure, Heart disease, Osteoarthritis, Polycystic Ovarian Syndrome (PCOS), Non-alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease, Gastroesophageal Reflux Disease (GERD), Depression, Anxiety, Weight-Related Psychosocial Distress, Stroke, Coronary Artery Disease, Metabolic Syndrome, Insulin Resistance, Body Pain, Infertility, Hypothyroidism, Sexual Dysfunction
Las autoridades sanitarias, como la Administracin de Alimentos y Frmacos (FDA) en Estados Unidos o el Instituto Nacional para la Excelencia en Salud y Atencin (NICE) en Reino Unido, sealan que el frmaco es seguro y efectivo para el control de peso crnico en adultos con obesidad que presentan al menos un trastorno vinculado con ese sobrepeso, como hipertensin o diabetes tipo 2
Mechanistically, Semaglutide and Liraglutide are both glucagon-like peptide-1 (GLP-1) receptor agonists, but Semaglutide has been modified to have a longer half-life and increased binding affinity, potentially contributing to its greater weight loss efficacy
The injectable may in fact be the better therapy for some people because its [taken] weekly versus the need to take the pill every day, he says
Aim for at least eight glasses a day, and more if you are exercising
